Mitch A. Phelps

Image
Mitch Phelps

Mitch A. Phelps, PhD

Title
Professor
Unit / Department / Division
Pharmaceutics and Pharmacology
Outcomes and Translational Sciences Affiliated Faculty
Address
612 Riffe Building
Email Address
Phone Number

Professional Interests

Professional Interests

Mitch Phelps’ group is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).

Education

  • 2005, PhD, The Ohio State University, Biophysics
  • 1999, MLHR, The Ohio State University, Labor and Human Resources
  • 1992, BA, Ohio Wesleyan University, Physics

Honors

  • Outstanding Graduate Student Award, 2005
  • Predoctoral Fellowship, 2004
  • Predoctoral Fellowship, 2003 - 2004
  • Ray Travel Award, 2003
  • Hazel Brown Teaching Award, 2001

Journal Articles

KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, Blachly JS, Call T, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CA, Carson WE, Jones JA, Grever MR. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021 Jun 24;137(25):3473-3483. doi: 10.1182/blood.2020009688. PMID: 33754642; PMCID: PMC8225920.

Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother Pharmacol. 2021 May;87(5):599-611. doi: 10.1007/s00280-020-04229-3. Epub 2021 Jan 25. PMID: 33492438; PMCID: PMC8162746.

Irby DJ, Ibrahim ME, Dauki AM, Badawi MA, Illamola SM, Chen M, Wang Y, Liu X, Phelps MA, Mould DR. Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):291-308. doi: 10.1002/psp4.12611. PMID: 33715307; PMCID: PMC8099444.

Safa A, Lau AR, Aten S, Schilling K, Bales KL, Miller VA, Fitzgerald J, Chen M, Hill K, Dzwigalski K, Obrietan K, Phelps MA, Sadee W, Oberdick J. Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model. Front Pharmacol. 2021 Feb 25;11:613328. doi: 10.3389/fphar.2020.613328. PMID: 33716726; PMCID: PMC7953910.

Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. Sci Rep. 2021 Feb 11;11(1):3646. doi: 10.1038/s41598-021-82252-x. PMID: 33574348; PMCID: PMC7878907.

Li J, Seligson N, Zhang X, Johnson J, Vangundy Z, Wang D, Phelps M, Hofmeister C, Sadee W, Poi MJ. Association of Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Res. 2020 Oct;40(10):5707-5713. doi: 10.21873/anticanres.14585. PMID: 32988896.

Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs. 2020 Oct;38(5):1400-1410. doi: 10.1007/s10637-020-00895-5. Epub 2020 Jan 17. PMID: 31953695; PMCID: PMC7955776.

Jain R, Coss C, Whooley P, Phelps M, Owen DH. The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. Curr Oncol Rep. 2020 May 15;22(6):54. doi: 10.1007/s11912-020-00916-9. PMID: 32409907.

Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drugs. 2020 Apr;38(2):340-349. doi: 10.1007/s10637-019-00786-4. Epub 2019 May 17. PMID: 31102119; PMCID: PMC6858927.

Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi MJ. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Mol Carcinog. 2019 Dec;58(12):2327-2339. doi: 10.1002/mc.23121. Epub 2019 Sep 22. PMID: 31544312.